证券简称:东星医疗 公告编号:2025-048 江苏东星智慧医疗科技股份有限公司 关于筹划重大资产重组的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假 记载、误导性陈述或重大遗漏。 一、交易概述 证券代码:301290 二、本次交易进展 2025年10月24日，公司披露了《关于筹划重大资产重组的进展公告》（公告编 号: 2025-043）。 截至本公告披露之日,标的公司的审计、评估工作正在进行中,预计尚需一定 时间完成,公司及相关各方正在积极推进本次交易的相关工作,后续公司亦将按照 相关法律法规的规定及时披露项目进展情况。 三、风险提示 1、本次交易尚处于初步筹划阶段,交易方案和交易条款仍需进一步论证和沟通 协商,上市公司及标的公司尚需分别履行必要的内外部决策、审批程序,存在未能 通过有关决策、审批程序的风险。公司将严格按照相关法律法规及《公司章程》的 规定履行有关的决策审批程序和信息披露义务。 2、本次交易存在不确定性，可能出现因外部环境变化导致交易条件发生变化， 进而导致交易终止的情况。敬请广大投资者注意投资风险。 3、根据《上市公司股票停复牌规则》《深圳证券交易所上市公司自 ...

Group 1: Financial Data - In the first ten months of 2023, RMB loans increased by 14.97 trillion yuan, indicating reasonable growth in loan scale and continuous optimization of credit structure [4][10] - As of the end of October, the total social financing scale was 437.72 trillion yuan, with a year-on-year growth of 8.5% [3][4] - The broad money (M2) balance reached 335.13 trillion yuan at the end of October, reflecting a year-on-year increase of 8.2% [4] Group 2: Government Initiatives - The Ministry of Commerce plans to enhance the "Export China" initiative through various activities to facilitate the entry of quality products and services into China [4] - The Ministry of Industry and Information Technology reported significant progress in 6G technology development, with over 300 key technologies reserved and collaboration with global equipment manufacturers [4][5] Group 3: Company News - Hezhong Group announced a potential change in control, leading to a stock suspension starting November 14, with a significant increase in net profit of 1091.01% reported for Q3 2025 [6][9] - Tencent Holdings reported Q3 2025 revenue of 1928.69 billion yuan, a 15% year-on-year increase, with a notable rise in R&D spending [10][12] - JD Group's Q3 2025 revenue reached 2990.6 billion yuan, marking a 14.9% year-on-year growth, while net profit decreased compared to the previous year [13] Group 4: Market Trends - The AI-driven demand for computing power and applications in the telecommunications sector is expected to grow, with a focus on key technologies for 6G development [14]

Core Viewpoint - Dongxing Medical reported that as of November 10, 2025, the total number of shareholders is 10,180, including credit accounts [2] Summary by Categories - **Company Information** - Dongxing Medical has a total of 10,180 shareholders as of November 10, 2025, which includes credit accounts [2] - **Investor Interaction** - The company responded to investor inquiries on its interactive platform regarding shareholder numbers [2]

Core Viewpoint - Dongxing Medical (301290) is making progress in its collaboration project with Shanghai Jiao Tong University, focusing on the construction of production lines for both long-chain and short-chain recombinant type III humanized collagen strains [1] Group 1 - The company is accelerating the development of its production lines for collagen strains [1] - The research results of the project are uncertain, and investors are advised to be cautious regarding investment risks [1]

Core Viewpoint - Dongxing Medical emphasizes that its stock price fluctuations are influenced by multiple complex factors, including market environment, investor preferences, and short-term speculation [2] Group 1: Company Strategy - The company remains focused on its core business and market demand [2] - Management is committed to improving operational performance and driving intrinsic value growth through continuous innovation [2] Group 2: Commitment to Shareholders - Dongxing Medical is dedicated to strengthening its fundamentals and achieving better performance to return value to shareholders and investors [2]

Group 1 - The company, Dongxing Medical, reported that as of October 31, 2025, the total number of shareholders is 10,407, including credit accounts [2]

Core Insights - Dongxing Medical (301290.SZ) reported its Q3 2025 results on October 29, 2025, highlighting a total of 8 institutional investors holding shares, amounting to 15.50% of the total share capital [1] Institutional Holdings - As of October 28, 2025, institutional investors collectively held 15.52 million shares of Dongxing Medical, a decrease of 1.36 percentage points compared to the previous quarter [1] - The institutional investors include various firms such as Changzhou Kaizhou Investment Management Co., Suzhou Jifeng Equity Investment Partnership, and Hainan Ping An Private Fund Management Co. [1] Public Fund Disclosures - In this reporting period, 32 public funds were not disclosed compared to the previous quarter, including funds like CITIC Jiankong Rotation Mixed A and Medical Device ETF [1]

Group 1 - Dongxing Medical (SZ 301290, closing price: 27.34 yuan) announced on October 29 that its fourth board meeting was held on October 28, 2025, to review the proposal regarding the full text of the "2025 Q3 Report" [1] - For the first half of 2025, Dongxing Medical's revenue composition was 82.23% from the medical device industry and 17.77% from other industries [1] Group 2 - The A-share market has surpassed 4000 points, marking a significant resurgence after ten years of stagnation, with technology leading the market and a new "slow bull" pattern emerging [1]

Core Insights - Dongxing Medical (301290) reported a revenue of 284 million yuan for the first three quarters of 2025, a year-on-year decline of 10.21%, with a net profit attributable to shareholders of -70 million yuan, down 263% year-on-year, primarily due to a goodwill impairment loss of approximately 100 million yuan recognized in the third quarter [1] Group 1: Business Performance - The company focuses on surgical medical devices, particularly in the field of anastomosis devices, and has two main business segments: surgical instruments represented by anastomosis devices and surgical equipment represented by operating tables and shadowless lamps [1] - In the anastomosis device sector, Dongxing Medical has emphasized the electric anastomosis device, achieving over 130% year-on-year revenue growth in 2024 [1] - The company has obtained a Class III medical device registration certificate for its self-developed fully electric laparoscopic anastomosis device, further solidifying its market position [1] Group 2: Market Trends - Industry data indicates that the anastomosis device market in China is expected to grow from 9.82 billion yuan in 2024 to 16.67 billion yuan by 2030, with electric laparoscopic anastomosis devices being a major growth driver, projected to have a compound annual growth rate of 16% during this period [1] Group 3: Strategic Initiatives - Dongxing Medical is actively expanding into synthetic biology by collaborating with research institutions such as Changzhou University and Shanghai Jiao Tong University to develop high-tech barrier materials like recombinant humanized collagen and mussel adhesive protein, aiming to launch innovative medical consumables for hemostasis and scar repair [2] - The company announced a significant advancement in its platform strategy by planning to acquire 90% of Wuhan Yijiaobao, which will allow it to enter the high-end orthopedic market and extend its industrial chain in surgical medical devices [3] - The acquisition is expected to accelerate the commercialization of synthetic biological materials and enhance the company's platform development [3]

证券代码：301290 证券简称：东星医疗 公告编号：2025-045 江苏东星智慧医疗科技股份有限公司 关于2025年第三季度报告披露的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 江苏东星智慧医疗科技股份有限公司(以下简称"公司")于2025年10月28日 召开第四届董事会第十三次会议，审议通过了《关于公司<2025年第三季度报告> 全文的议案》。 为使投资者全面了解公司2025年第三季度的经营成果及财务状况，公司《 2025年第三季度报告》全文于2025年10月29日在中国证券监督管理委员会指定 的创业板信息披露网站巨潮资讯网(www.cninfo.com.cn)上进行披露。 董事会 2025年10月29日 敬请广大投资者注意查阅。 特此公告。 江苏东星智慧医疗科技股份有限公司 ...